Vivani Medical (VANI) Stock Price, Quote, News & History | Benzinga

SPY778.57+0.60%QQQ751.38+0.51%BTC/USD83,567.47−0.13%DIA516.21+0.89%GLD384.50+1.55%TLT77.97+0.12%

Vivani Medical Inc (VANI) Stock Price, Quote, News & History

VANINASDAQ

Trade with Public

Trade with Public

$1.25

0.021.63%

Last update: Oct 9, 4:00 PM

$1.21

-0.02-1.63%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$1.22

Close

$1.25

Volume / Avg.

101.72K / 275.61K

Day Range

$1.24 - $1.24

52 Wk Range

0.92 - 1.92

Market Cap

$110.95M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

48

Short Interest

1.1%

Days to Cover

2.56

Recent Vivani Medical Inc News

EXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data

Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss from a single dose.

Vandana Singh

EXCLUSIVE: Vivani Medical Collaborates With Okava To Expand Development Of GLP-1 Therapy For Dogs

Vivani Medical and Okava expand GLP-1 therapy research to dogs, aiming to advance long-acting treatments for cardiometabolic conditions.

Vandana Singh

EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosing

Vivani Medical's NPM-139 semaglutide implant showed steady drug release and nearly 20% weight loss in preclinical studies, supporting long-term weight management.

Vandana Singh

EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management. Top-line results are expected by mid-2025.

Vandana Singh

EXCLUSIVE: Vivani Medical To Spin Off Cortigent Neurostimulation Business To Create Better Focus On Individual Entities And Shareholder Value

Vivani Medical plans to spin off Cortigent into a separate public company, aiming to expand neurostimulation technology while focusing on its drug implants.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-25.30M

Investing Cash Flow (TTM)

-1.20M

Financing Cash Flow (TTM)

39.09M

Free Cash Flow (TTM)

-26.50M

Capital Expenditure (TTM)

-1.20M

Net Change in Cash (TTM)

12.59M

Analyst Trends and Forecast

1

Jun

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$109.81M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

5.85

Earnings Yield % (TTM)

-29.27%

Earnings Yield % (FWD)

-26.02%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.21

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$320.00K

Total Cash

$19.89M

Debt to Equity

0.94

Issuance of Debt (TTM)

-$320.00K

Repayment of Debt (TTM)

-$320.00K